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Summary A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres
composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal
carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks. Intraperitoneal 5FU-
MS distributed higher concentrations of 5FU to the intraperitoneal tissues, such as the omentum and the
mesentery, for a longer period with lower blood plasma concentrations than did the aqueous 5FU solution in
rats. In experiments using mice, the lethal toxicity, determined by the probit method, in 5FU-MS was reduced
to less than half that in aqueous 5FU solution. We evaluated the therapeutic effects on peritoneal
carcinomatosis induced by the intraperitoneal inoculation of B-16 PC melanoma cells. The therapeutic effects
of 5FU-MS were enhanced when compared with both the equivalent doses and same toxicity doses of the
aqueous 5FU solution.
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Intraperitoneally administered anti-cancer drugs in an
aqueous solution are one of the most common treatments
for peritoneal carcinomatosis. However, it is not always
effective, because small, water-soluble molecules, such as 5-
fluorouracil (5FU) in aqueous solution, are rapidly absorbed
through the blood capillaries into the systemic circulation
(Ruszynak et al., 1967), and it is difficult to maintain the
concentration at high levels for long periods of time in the
target area (Speyer et al., 1980). In contrast, corpuscular
particles such as microspheres, are retained in the peritoneal
cavity for long periods (Ruszynak et al., 1967).
Using the difference in absorption through the peritoneum
between aqueous solutions and corpuscular particles, a new
5FU formulation (5FU-MS) consisting of microspheres
incorporating 5FU, was developed. 5FU-MS is designed to
release the incorporated 5FU slowly for 3 weeks at the site
where the particles of 5FU-MS are retained. These
characteristics of 5FU-MS indicate that intraperitoneal
5FU-MS will maintain the 5FU concentration at a higher
level for a longer period of time in the peritoneal cavity,
while exposing the rest of the body tissues to lower
concentrations of 5FU. Thus, one would expect that 5FU-
MS will decrease systemic toxicities and increase the local
therapeutic effects in the peritoneal cavity, as compared with
an aqueous 5FU solution.
This paper reports the drug distribution, systemic toxicity
and therapeutic efficacy of 5FU-MS in animals.
Materials and methods
Drug preparation and in vitro characteristics
For the experiments, we used poly (glycolide-co-lactide)
(Biodegmer; Biomaterials Universe, Kyoto, Japan; an
average molecular weight of 14 000), as a biodegradable
substance (Ogawa et al., 1988), to synthesise the microspheres
and serve as a drug carrier. 5-fluorouracil (5FU, a gift from
Kyowa Hakko Koygo, Tokyo, Japan) was used as the anti-
cancer drug.
A new 5FU formulation (5FU-MS), consisting of 5FU
incorporated in microspheres of poly (glycolide-co-lactide)
matrix was prepared using a water-in-oil emulsion method.
5FU (10 mg ml-') and 90 mg ml-' of poly (glycolide-co-
lactide) were dissolved in 97% acetic acid. The resulting
solution was emulsified in 10 volumes of liquid paraffin by
stirring at 250 r.p.m. at 30°C for 2 days. The emulsion was
made into microspheres containing 5FU using an evapora-
tion method. The microspheres were vacuum dried for 2 days
and sieved. The fraction with an average diameter of 24 ,um
was used for the study. A suspension of 5FU-MS in saline
with 0.01% Tween 80 to keep the microspheres well dispersed
was administered. As a control, an aqueous solution of 5FU
for clinical use (5-FU Kyowa, Kyowa Hakko Kogyo Co Ltd)
was diluted with saline or with saline containing 0.01%
Tween 80 to yield the required concentration of aqueous
5FU.
The animals received humane care according to the
institutional guidelines for the use of animals in research,
testing, and education.
Drug distribution
In the drug distribution experiment, rats were used as an
experimental animal so that a sufficient volume of sample
tissues should be taken for measurement of drug concentra-
tion. At least 1 g of sample tissue is necessary for the exact
determination of drug concentration in the tissue. The weight
of organs is much greater (approximately 10-fold) in rats
than in mice.
Fifty male rats (Wistar strain, weighing 150 g, Shimizu
Laboratory Animal Center, Kyoto, Japan) were bred under
standard conditions (specific pathogen-free, room tempera-
ture of 22°C, relative humidity of 60%, day-night cycle of
12 h). The rats were divided into two equal groups.
A dose of 150 mg kg-' 5FU, in 6 ml, was administered
intraperitoneally to each rat in the two groups in the form of
5FU-MS or an aqueous 5FU solution. Five rats from each
group were sacrificed 1, 6 and 24 h and 4 and 16 days after
the administration of the drug. Blood was collected to
measure the drug concentration delivered to the rest of the
body. The blood plasma was separated from blood cells by
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the mesentery were resected for samples of intraperitoneal
tissues, since the majority of intraperitoneally seeded
malignant cells implanted in the omentum and the mesentery
rather than in other sites (Hagiwara et al., 1993a). The
plasma, omentum and mesentery were stored at - 100°C. The
concentration of 5FU in these samples was measured by
high-performance liquid chromatography (Jones et al., 1979)
(LC-6A System; Shimazu, Kyoto, Japan) with absorption
spectroscopy at a wave-length of 264 nm (Masuike et al.,
1979). The sensitivity of 5FU assay was 10 ng ml-' or g-'.
When the 5FU concentration was less than the assay limit
in two or more samples out of the five samples taken at the
same time point, the 5FU concentration was considered to be
'not detectable'. The 5FU concentrations were compared
statistically by analysis of variance between the two dosage
formulations, when the 5FU concentrations in both
formulations were 'detectable'.
Toxicity
A total of 119 male BDF1 mice (5 weeks, body weight of
20 g, Shimizu Laboratory Animal Center) were divided into
17 groups composed of seven mice each. Seven groups
received intraperitoneal 5FU-MS. Eight groups received
intraperitoneal 5FU aqueous solution and one control group
received intraperitoneal empty microspheres. The remaining
group received no drugs.
The drugs were administered intraperitoneally with a 20-
gauge needle in 1 ml of saline containing 0.01% Tween 80 on
day 0. In the seven groups receiving 5FU-MS intraperitone-
ally, the 5FU dose ranged from 267.9 to 800.0 mg kg-' of
body weight, and the doses in the seven groups were
increasing serially by a factor of 1.20. In the eight groups
receiving the aqueous 5FU solution, the 5FU dose, ranging
from 134.0 to 480.0 mg kg-' of body weight, was injected
intraperitoneally. The doses in the eight groups were
increased serially by the same factor. One control group
received 7.2 g kg-' of empty microspheres, a quantity of
microspheres equal to that contained in 5FU-MS at a 5FU
dose of 800 mg kg-'.
The mice were maintained under standard conditions, and
were observed for 21 days after the administration of the
drugs. Mice were sacrificed when they became moribund. The
day of death was recorded. The 10%, 50% and 90% lethal
dose values (the LDIO, LD50 and LD90 values) for each drug
were calculated by the probit method.
Therapeutic effects
A total of 280 male BDF1 mice, aged 5 weeks and
maintained under standard conditions, were used. B-16 PC
melanoma (Hagiwara et al., 1993a), which was established
from the standard mouse malignant melanoma B-16 cell line
and which induces peritoneal carcinomatosis when inoculated
intraperitoneally, was the experimental tumour. B-16 PC
melanoma cells were suspended in Hank's solution. The cell
viability was greater than 95%, as determined by the trypan
blue exclusion test. A dose of 106 cells per mouse of free cells
was inoculated intraperitoneally into the mice on day 0.
The drugs were given intraperitoneally in a total volume of
1 ml on day 4, because a preliminary experiment showed that
intraperitoneally inoculated B-16 PC melanoma cells had
established peritoneal metastases 4 days after the inoculation.
The mice were divided into 14 groups, composed of 20 mice
each. Five groups received the 5FU-MS (the 5FU-MS
groups), six groups received the aqueous 5FU solution (the
5FU solution groups), one group received empty micro-
spheres (the empty-MS group), another group received the
empty microspheres plus the 5FU solution (the empty-
MS+ 5FU solution group), and the last group received no
treatment (the non-tre.atment group). In the 5FU-MS groups,
a suspension of 5FU-MS, yielding a 5FU dose of
100 mg kg-', 150 mg kg-', 200 mg kg-', 300 mg kg-' or
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400 mg kg-' (which was approximately equal to the LDjo
value) was given. In the 5FU solution groups, a 5FU dose of
100 mg kg-', 150 mg kg-' or 200 mg kg-' (which was
approximately equal to the LDIo value) was given in normal
saline or in saline with 0.01% Tween 80. Since the 5FU-MS
group receiving 200 mg kg-' in terms of 5FU also received
1.8 g kg-' of microspheres, the empty-MS group was given
1.8 g kg-' of a microsphere suspension without 5FU. In the
empty-MS+5FU solution group, 200 mg kg-' of the 5FU
solution plus 1.8 g kg-' of the empty microspheres were
given. After 150 days, the survivors were sacrificed and
examined for cancer tissues microscopically. Dead mice
underwent autopsy and were examined macroscopically and
microscopically to determine whether the cause of death was
due to drug toxicity or cancer.
The therapeutic effect on the survival times between the
various formulations was compared at doses with equivalent
toxicity, as well as at the same 5FU doses, by the generalised
Wilcoxon test.
Statistical methods
When the P-value was less than 0.05, the difference was
considered to be statistically significant.
Results
Drug distribution
The concentrations of 5FU in the omentum and the
mesentery are shown in Tables I and II, respectively, as are
the concentrations in the tissues located in the intraperitoneal
cavity. In the 5FU-MS group, the 5FU concentration in the
omentum remained at a high level, and was greater (39-fold
to 1153-fold) than that in the 5FU solution group throughout
the observation period of 16 days after administration. The
5FU concentration between the two dosage formulations was
Table I 5FU concentration in the omentum
SFU concentration
Mean value (pg g-')
Time after (95% confidence interval) Statistical
administration 5FU-MS group SFU solution group significance
1 h 551 14.2 P<0.01
(304-798) (-233-261)
6 h 693 2.1 P<0.025
(326-1060) (-364-369)
24 h 363 1.3 NS
(-166-893) (-228-231)
4 days 153 0.21 P<0.05
(21.6-285) (-22.4-22.8)
16 days 17.3 0.015 NS
(3.06-31.6) (-14.3- 14.3)
NS, not significant.
Table II 5FU concentration in the mesentery
SFU concentration
Mean value (pg g'-)
Time after (95% confidence interval) Statistical
administration SFU-MS group SFU solution group significance
1 h 12.7 30.3 P<0.025
(3.14-22.4) (20.7-39.9)
6 h 261.5 2.25 P<0.05
(68.6-542) (69.4-69.4)
24 h 61.0 1.08 P<0.05
(21.1-101) (-17.0- 19.1)
4 days 22.2 0.297 P<0.05
(7.08-37.4) (-14.8- 15.4)
16 days 1.70 ND
(0.349-3.04)
ND, not detectable.5FU-MS for carcinomatous peritonitis
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significantly (P<0.01 to 0.05) different at 1 h, 6 h and at 4
days after drug administration.
In the mesentery, the 5FU concentration in the SFU-MS
group was 12.7 ,ug g-1, which was smaller than that
(30.3 ig g-1) in the 5FU solution group at 1 h after
administration, but increased to 261.5 pg g-' at 6 h and
remained at a relatively high level for 16 days. On the other
hand, in the 5FU solution group, the 5FU concentration in
the mesentery rapidly decreased from 30.3 ig g-' at 1 h to a
'not detectable' level 16 days after injection. The SFU
concentration in the mesentary was significantly different
(P<0.025 to 0.05) at 1 h, 6 h, 24 h and 4 days between the
two dosage formulations.
The 5FU concentration in the blood plasma served as an
indicator of 5FU exposure of the extraperitoneal tissues in
the rest of the whole body (Table III). In the 5FU-MS group,
the 5FU concentration remained at a lower level throughout
the observation period of 16 days. In the SFU solution
group, the 5FU concentration was significantly higher (32-
fold at 1 h, P<0.005; 150-fold at 6 h, P<0.05) than that in
the 5FUsMS group, and then the concentration rapidly
decreased to the 'not detectable' level at 4 days after
administration.
Toxicity
The acute lethal toxicity is represented in Table IV. The
LDIo, LD,0 and LD90 values for 5FU-MS in terms of the
5FU dose were 382.8 mg kg-', 535.4 mg kg-' (472.4-
611.1 mg kg-' at the 95% level of confidence) and
748.8 mg kg-' respectively. The LD1o, LD50 and LD90 values
for the SFU solution were 179.4 mg kg-', 241.6 mg kg-'
(215.4-270.8 mg kg-' at 95% level of confidence) and
325.5 mg kg-'. Thus, the toxicity of 5FU-MS was reduced
to 45.1% of the soluble 5FU.
Microspheres without 5FU (the empty microspheres)
caused no toxic symptoms nor deaths.
Therapeutic effects
The mice that survived for 150 days were cancer free, as
determined by autopsy. Two mice given 400 mg kg-1
Table III SFU concentration in blood plasma
5FU concentration
Mean value (Mg g'-)
Time after (95% confidence interval) Statistical
administration 5FU-MS group 5FU solution group significance
1 h 1.57 50.0 P<0.005
(-9.39- 12.5) (39.0-61.0)
6 h 0.028 4.20 P<0.05
(-1.7- 1.7) (1.9-6.5)
24 h 0.020 0.055 NS
(-0.020-0.060) (0.015-0.096)
4 days 0.013 ND
(0.000-0.026) -
16 days ND ND
NS, not significant; ND, not detectable.
Table IV Acute toxicity in mice
Dosage LDIO valuea LD50 valuea LD90 valuea
formulation (95% confidence interval) in terms of 5FU in mg kg-'
5FU-MSb 382.8 535.4 748.8
(472.4-611.1)
SFU solution 179.4 241.6 325.5
(215.4-270.8)
aLD1O value, LD50 value and LD90 value, the 10%, 50% or 90%
lethal dose value. bSFU-MS, SFU incorporated in microspheres.
5FU in the form of SFU-MS died on days 16 and 17, and
seven mice given 200 mg kg-' SFU in the form of aqueous
SFU solution died on days 10 and 11. In those mice, they had
no or little cancerous tissues but remarkable toxic changes,
such as atrophy of lymphatic tissues. The mice were
considered dead from drug toxicity. On the contrary, for
the mice dead on later dates, lots of cancerous tissues were
found growing in the peritoneal cavity with ascites fluid. It
was concluded that they died as a result of peritoneal
carcinomatosis.
The results of the therapeutic experiments are shown in
Table V. 5FU-MS increased survival with increasing 5FU
doses: the median survival was 28.5 days (T/C% of 124%)
with a 5FU dose of 100 mg kg-' and more than 150 days
(T/C % of more than 652%) with a dose of 400 mg kg-',
which was a slightly larger dose than the LD,o value. On the
other hand, 5FU solution was not as efficacious when 5FU
dose was increased: the median survival was 28 days (T/C
% of 122%) with a 5FU dose of 100 mg kg-' and only 29.5
days (T/C % of 128%) with a dose of 200 mg kg-', which
was a slightly larger dose than the LD,0 value.
The survival times between the SFU-MS group and the
SFU solution group were compared at the same SFU
doses. A SFU dose of 200 mg kg-' in SFU-MS formulation
prolonged the survival time significantly (P<0.05 to 0.01),
as compared with the same dose of aqueous SFU. There
was no significant difference between the SFU-MS group
and the SFU solution group in the survival times of mice
treated with 150 mg kg-' or 100 mg kg-' SFU.
As the toxicity experiments indicate, SFU-MS is less toxic
than half the dose of the SFU solution. Therefore, the
therapeutic effects were compared between the mice treated
Table V Therapeutic effects on peritoneal carcinomatosis in mice
Median No. of
Treatment survival No. of toxic
group Days Range T/C(%)a survivorsb deathsc
(1) 5FU-MSd > 150 >652 11 2
400 mg kg-' (16 to> 150)
(2) 5FU-MS 36 157 6 0
300 mg kg-' (33 to> 150)
(3) 5FU-MS 32 139 2 0
200 mg kg-' (27 to>150)
(4) 5FU-MS 30 130 0 0
150 mg kg' (25-41)
(5) 5FU-MS 28.5 124 0 0
100 mg kg-' (25-34)
(6) 5FU solutione 29.5 128 0 3
200 mg kg'1 (10-39)
(7) 5FU solutionf 29.5 128 0 2
200 mg kg-' (11-37)
(8) 5FU solutione 29.5 128 0 0
150 mg kg-' (26-35)
(9) 5FU solutionf 29 126 0 0
150 mg kg-' (26-33)
(10) 5FU solutione 28 122 0 0
100 mg kg'f (24-31)
(11) 5FU solutionf 28 122 0 0
100 mg kg'I (24-32)
(12) Empty-MS +
5FU solution 29 126 0 2
200 mg kg-' (11-35)
(13) Empty-MS 24 104 0 0
(20-27)
(14) Non-treatment 23 100 0 0
(20-26)
'T/C(%), Median survival day in the treatment group/median
survival day in the non-treatment group. bNo. ofsurvivors, number of
mice surviving for 150 days after cancer cell inoculation. cNo. oftoxic
deaths, number of mice dead from drug toxicity, as determined by
autopsy. dSFU-MS, the new dosage formulation of 5-fluorouracil
incorporated in microspheres. eSFU solution in normal saline
containing 0.01% Tween 80. f5FU solution in normal saline.5FU-MS for carcinomatous peritonfits
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with 5FU-MS and the mice treated with half the equivalent
dose of the 5FU solution. The survival times of the mice
treated with 5FU-MS were significantly better than those of
the mice treated with half the respective 5FU solution
(200 mg kg-' 5FU-MS vs 100 mg kg-' 5FU solution:
P<0.05; 300 mg kg-' 5FU-MS vs 150 mg kg-' 5FU
solution: P<0.01; 400 mg kg-' 5FU-MS vs 200 mg kg-'
5FU solution: P<0.01). Thus, intraperitoneal 5FU-MS had
a superior therapeutic effect over the same dose of the 5FU
solution, as well as half the dose, which had a mildly greater
toxicity than did the 5FU-MS.
There was no difference in the therapeutic effect between
the mice given the 5FU solution and the mice given the 5FU
solution plus empty microspheres. The empty microspheres
caused neither toxic death nor prolongation of survival.
Discussion
Peritoneal carcinomatosis is one of the most common modes
of post-operative recurrent disease in digestive cancers and
ovarian cancer. Therefore, effective management of peritoneal
carcinomatosis is necessary to improve the post-operative
survival of patients with such cancers.
Small particles, such as microspheres, are gradually
absorbed selectively through milky spots, which are a kind
of lymphatic apparatus located on the peritoneal surface
(Mandache et al., 1989). We have shown that the milky spots
are the site at which intraperitoneally seeded malignant cells
are implanted selectively (Hagiwara et al., 1993a; Tsujimoto
et al., 1995). It means that intraperitoneal microspheres and
other particles containing anti-cancer drug can target the
malignant cells which are implanted in the peritoneum
(Hagiwara et al., 1996). Based on this idea, we developed
another dosage formulation of activated carbon particles
adsorbing mitomycin C (M-CH). M-CH has superior
therapeutic effects on peritoneal carcinomatosis in animal
experiments (Hagiwara et al., 1988). In clinical study, M-CH
improves survival in patients with gastric cancer by a
prophylactic effect on peritoneal carcinomatosis (Hagiwara
et al., 1992). M-CH is composed of mitomycin C adsorbing
activated carbon particles, which are not degradable in vivo.
As biodegradable particles of drug carrier for intraperitoneal
chemotherapy, we have developed the microspheres. Before
5FU-MS, we developed two other types of microspheres
incorporating cisplatin and doxorubicin (CDDP-MS and
DOX-MS respectively) for intraperitoneal chemotherapy
(Hagiwara et al., 1993b). In our experiments using animals,
CDDP-MS and DOX-MS were not as satisfactory: CDDP-
MS had reduced systemic toxicity but also inferior
therapeutic efficacy compared with the same dose of an
aqueous cisplatin solution. CDDP-MS prolonged the survival
time to 1.3-fold that of animals receiving an aqueous cisplatin
solution with the same toxicity, while the comparable result
with 5FU-MS was more than 5-fold. Thus, there was a small
difference observed by changing the dosage formulation of
CDDP. Intraperitoneal DOX-MS caused severe peritoneal
adhesions and intestinal obstruction in rats. We concluded
that DOX-MS is unsuitable for intraperitoneal chemother-
apy.
5FU is one of the most efficacious anti-cancer drugs
against many cancers, and intraperitoneal 5FU achieves good
control of peritoneal carcinomatosis (Sugarbaker et al.,
1985). However, intraperitoneal 5FU is readily absorbed
into the systemic circulation (Speyer et al., 1980), causing a
rather steep decline in its concentration in the intraperitoneal
tissues (Jones et al., 1978). As an excellent method for
intraperitoneal chemotherapy, continuous intraperitoneal
infusion of 5FU has been developed using a totally
implantable device (Gyves et al., 1984). This method
distributes a highly concentrated dose of 5FU to the
intraperitoneal space for a prolonged period of time.
However, even by this method, 5FU in an aqueous solution
form cannot target the malignant cells implanted in the milky
spots.
The intraperitoneal administration of 5FU-MS, which is a
convenient method, distributes a high concentrations of 5FU
selectively into the intraperitoneal tissues over a long period
of time, as shown in the present experiments on drug
distribution. Since the anti-cancer activity of 5FU depends on
the length of time as well as on its concentration (Inaba et
al., 1990), its therapeutic effects on peritoneal carcinomatosis
are enhanced with the 5FU-MS formulation. The drug
distribution experiments showed that the 5FU concentra-
tions in blood plasma were lower in the rats given 5FU-MS
than in those rats given the 5FU solution. This result suggests
that 5FU-MS causes less systemic toxicity than does the same
dose of aqueous 5FU, which was confirmed in the toxicity
experiments. These results suggest that intraperitoneal 5FU-
MS may be more efficacious in the treatment of peritoneal
carcinomatoses, because it yields enhanced therapeutic effects
and reduced systemic toxicity in these animal studies.
Abbreviations
5FU, 5-fluorouracil; 5FU-MS, 5-fluorouracil incorporated in
microspheres composed of poly(glycolide-co-lactide) matrix.
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